Cardiol Res

Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access

Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc

Journal website https://www.cardiologyres.org

Original Article

Volume 15, Number 4, August 2024, pages 246-252

The Predictive Role of Cardiac Troponin Elevation Ratio Combined With Heart Function Index Model in the Prognosis of Non-ST-Segment Elevation Myocardial Infarction Patients

Figures

Figure 1. The correlation between the rate of elevation of cardiac troponin and the mortality rate. Optimal cut-off value = 36.25-fold; AUC = 0.707, sensitivity = 90.9%, specificity = 47.5%. AUC: area under the curve; ROC: receiver operating characteristic.

Figure 2. Nomogram and calibration curves for predicting the probability of death in NSTEMI patients. (a) Nomogram for prediction with the following variables: H-CRP elevated = 1; sex: 1 = male; LVEF < 50% = 1; cTnI/ULN > 36.25 times = 1; NYHA class III and IV = 1. (b) Calibrate curve of the nomogram. The C-index of this nomogram is 0.911. (c) The receiver operating characteristic (ROC) curve of the nomogram with an AUC of 0.911. The sensitivity and specificity were 72.8% and 95.1%, respectively. NYHA: New York Heart Association; LVEF: left ventricular ejection fraction; cTnI: cardiac troponin I; ULN: upper limit of normal; AUC: area under the curve.

Figure 3. The predictive efficacy of the Grace score. AUC = 0.840, 95% CI: 0.728 - 0.953, P < 0.001. AUC: area under the curve; CI: confidence interval.

Table

**Table 1.** Demographic and Clinical Characteristics of the Study Population
Characteristics	Total (n = 251)
IQR: interquartile range; NYHA: New York Heart Association; LVEF: left ventricular ejection fraction; cTn: cardiac troponin; LDL: low-density lipoprotein; H-CRP: high-sensitivity C-reactive protein; HCY: homocysteine; UA: uric acid.
Age
≤ 44	12 (4.8%)
45 - 64	81 (32.3%)
≥ 65	158 (62.9%)
Median age (IQR)	70.0 (56 - 78)
Gender
Female	72 (28.6%)
Male	179 (71.3%)
NYHA class
I	170 (67.7%)
II	54 (21.5%)
III	20 (7.9%)
IV	7 (2.7%)
LVEF (%)	59.9±9.1%
cTn (ng/mL)	14.6 ± 74.2
Creatinine (µmol/L)	114.6 ± 131.5
LDL (mmol/L)	2.8 ± 1.0
HCY (µmol/L)	20.2 ± 21.9
H-CRP (mg/L)	2.5 ± 4.1
UA (µmol/L)	376.3 ± 116.7
Comorbidities
Hyperlipemia	74 (29.4%)
Hypertension	158 (62.9%)
Diabetes mellitus	61 (24.3%)
Treatment strategies
Antiplatelet therapy	251 (100%)
Stent implantation	226 (90.04%)
Anticoagulant therapy	151 (60.16%)